Merck 019-00 BENCHMRK
A multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety and antiretroviral activity of MK-0518 in combination with an optimized baackground therapy, versus optimized...
Bristol Myers Squibb IMPACT
IMPACT – A phase IV, multi-center, cross-sectional study to evaluate the 150L substitution among subjects experiencing Virologic failure on a HAART regimen containing Atazanavir. LABS ONLY – one...
Hoffman-LaRoche NV 17751
T-20 - Prospective observational cohort study of pneumonia in Fuzeon-exposed and non-exposed patients. Chart review only.
Inclusion criteria - Treatment experienced, CD4 < and/or = 400, Fuzeon...
|
